Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25383840 | 1.00 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL25386564 | 1.00 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL10316755 | 1.00 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL3885284 | 0.97 | FFAR1 (0.31) | FFAR1CPT2TDP1 | |
| SCHEMBL25385601 | 0.90 | TSHR (0.40) | FFAR1CPT2TDP1 | |
| SCHEMBL25386266 | 0.90 | TSHR (0.40) | FFAR1CPT2TDP1 | |
| SCHEMBL25385475 | 0.90 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL25383476 | 0.90 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL25384437 | 0.90 | TSHR (0.40) | FFAR1CPT2TDP1 | |
| SCHEMBL588096 | 0.90 | FFAR1 (0.34) | FFAR1CPT2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024018761-A1 | NEUTRAL LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| US-20240024252-A1 | LIPID NANOPARTICLE | NITTO DENKO CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| WO-2024018762-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| WO-2023188830-A1 | LIPID NANOPARTICLES | 国立大学法人北海道大学 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023191050-A1 | PHARMACEUTICAL COMPOSITION FOR DELIVERY TO CANCER, OR IMMUNOSTIMULATING COMPOSITION | 日東電工株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-4223314-A1 | LIPID NANOPARTICLE | National University Corporation Hokkaido University (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116367718-A | Lipid nanoparticles | 国立大学法人北海道大学 | 2023-06-30 | — | — | CN | disclosed |
| US-6433236-B1 | ISOMERIZATION CATALYST | ARTEVA NORTH AMERICA S.A.R.L. (CH) | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024252-A1 | LIPID NANOPARTICLE | LIPC, ACOX1, ABCB4 | FFAR1 359/4885CPT2 427/4885TDP1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.